Alyeska Investment Group
PHAS

Alyeska Investment Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Alyeska Investment Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-68,054
Closed -$893K – 535
2019
Q2 		$893K Buy
+68,054
New +$834K 0.01% 373
2019
Q1 		– Sell
-191,602
Closed -$592K – 472
2018
Q4 		$592K Buy
+191,602
New +$759K 0.01% 327

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's PHAS Position: Q3 2019 in Review

Alyeska Investment Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2019, closing a stake of 68,054 shares — an estimated $893K sold.

Alyeska Investment Group first reported a position in PHAS in Q4 2018 and held it in 2 quarters. The position peaked at $893K in Q2 2019. 58 funds tracked by Wall St. Rank hold PHAS as of Q3 2019.

  • Alyeska Investment Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 68,054 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $893K.
  • Alyeska Investment Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Alyeska Investment Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $893K in Q2 2019.
  • 58 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Alyeska Investment Group's 13F filing for Q3 2019, filed 14 Nov 2019.